$OCS

Oculis secures FDA agreement on Phase 3 trial design for Privosegtor optic neuritis treatment, de-risking regulatory pathway and clearing way for future drug submission.

Oculis secures FDA Special Protocol Assessment for Privosegtor Phase 3 trial, de-risking path to potential $7 billion optic neuritis market.

Oculis-backed research reveals significant unmet needs in diabetic macular edema treatment, with 60% of patients remaining untreated due to invasive therapies.

Oculis' DME AWARE study confirms expert demand for non-invasive treatment; OCS-01 eye drops target June 2026 Phase 3 results as potential first-in-class DME therapy.

Oculis will present its ophthalmology pipeline at ARVO 2026, with Phase 3 results for lead DME candidate OCS-01 expected in June.

Oculis to present advancing ophthalmology pipeline at ARVO 2026, with Phase 3 OCS-01 DME results expected June 2026.

Oculis announces investor conference participation ahead of landmark 2026 featuring multiple drug readouts and regulatory designations across three lead programs.

Oculis secures EMA PRIME fast-track designation for Privosegtor, a potential first-in-class neuroprotective optic neuritis therapy, following FDA Breakthrough status in January 2026.

Oculis' neuroprotective candidate Privosegtor receives EMA PRIME designation for optic neuritis, following FDA Breakthrough designation and positive Phase 2 data.

Oculis presents Phase 2 ACUITY trial results for Privosegtor at neuro-ophthalmology conference, showing vision improvements. Breakthrough therapy advances to registrational PIONEER program.

Oculis presents Phase 2 data for Privosegtor, an FDA Breakthrough-designated optic neuritis therapy showing improved visual acuity and reduced nerve damage, advancing toward Phase 3 registration trial.

Oculis files 2025 audited financial statements with SEC via Form 20-F and announces investor conference participation, signaling transparent capital markets engagement.

Oculis announces March 2026 investor conference participation, showcasing pipeline advances including Privosegtor's optic neuritis breakthrough designation and anticipated Phase 3 readouts.

Oculis plans March 2026 investor conferences highlighting six pivotal clinical readouts, including Privosegtor's breakthrough optic neuritis program and OCS-01 Phase 3 results expected Q2 2026.

Oculis appoints Katie Kazem as Chief Legal Officer. She brings 15+ years of life sciences legal expertise to support the company's three late-stage clinical programs.

Oculis appoints seasoned legal executive Katie Kazem as Chief Legal Officer to strengthen governance as it advances clinical pipeline with late-stage therapeutic candidates.